Exogenous creatine kinase and platelet aggregatio

Completed

• Conditions: Bleeding; platelet aggregation disorder; 10011082; 10014523

• Registration Number: NL-OMON40674
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Women between 18 and 50 years old, with no known disease or drug use.

Exclusion Criteria

Current disease, personal and family history of bleeding or coagulation abnormalities, intensive exercise in the three days prior to participation, drug use, use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) in the two weeks prior to participation, usage of the supplement creatine (or a creatine analogue), current smoking.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>ADP induced platelet aggregation (area under curve and final aggregation) with<br /><br>different concentrations of creatine kinase added in vitro.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Endogenous plasma CK activity levels.</p><br>